Methotrexate at middle and high accumulative doses might be associated with lower risk of new-onset cancers in patients with rheumatoid arthritis: a nationwide population-based cohort study.
Wuu-Tsun PerngYao-Min HungRenin ChangCheng-Li LinJeng-Yuan ChiouHuang-Hsi ChenChia-Hung KaoJames Cheng-Chung WeiPublished in: Therapeutic advances in musculoskeletal disease (2020)
MTX at middle and high accumulative doses might be associated with lower risk of new-onset cancers in patients with RA.